Stock analysts at StockNews.com initiated coverage on shares of NanoViricides (NYSE:NNVC – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.
NanoViricides Stock Up 0.9 %
NanoViricides stock opened at $1.15 on Tuesday. NanoViricides has a 52 week low of $1.00 and a 52 week high of $2.00. The company has a market capitalization of $13.55 million, a price-to-earnings ratio of -1.42 and a beta of 0.67. The stock has a 50-day moving average price of $1.21 and a 200 day moving average price of $1.16.
NanoViricides (NYSE:NNVC – Get Free Report) last announced its quarterly earnings results on Wednesday, February 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01.
NanoViricides Company Profile
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
See Also
- Five stocks we like better than NanoViricides
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- High-Yield Texas Instruments Could Hit New Highs Soon
- Compound Interest and Why It Matters When Investing
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
